Polymerases, compositions, and methods of use

US12077789B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12077789-B2
Application numberUS-202217829866-A
CountryUS
Kind codeB2
Filing dateJun 1, 2022
Priority dateAug 14, 2021
Publication dateSep 3, 2024
Grant dateSep 3, 2024

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Presented herein are altered polymerase enzymes for improved incorporation of nucleotides and nucleotide analogues, in particular altered polymerases that maintain low pre-phasing rates when using ambiently stored polymerases, as well as methods and kits using the same.

First claim

Opening claim text (preview).

The invention claimed is: 1. A recombinant family B archaeal DNA polymerase comprising an amino acid sequence that is at least 80% identical to a DNA polymerase amino acid sequence SEQ ID NO:8 or 12, wherein the recombinant DNA polymerase comprises at least two substitution mutations, wherein the first substitution mutation at the position functionally equivalent to Ala408 comprises a mutation to Tyr, and wherein the second substitution mutation at the position functionally equivalent to Ala409 comprises a mutation to Pro, and wherein the recombinant DNA polymerase preferentially incorporates a nucleotide having a blocking group at a faster rate than a nucleotide lacking the blocking group. 2. A recombinant family B archaeal DNA polymerase comprising an amino acid sequence that is at least 80% identical to a DNA polymerase amino acid sequence SEQ ID NO:8 or 12, wherein the recombinant DNA polymerase comprises at least two substitution mutations, wherein the first substitution mutation at the position functionally equivalent to Ala408 comprises a mutation to Tyr, and wherein the second substitution mutation at the position functionally equivalent to Ala409 comprises a mutation to Pro, and further comprising at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, or at least nine amino acid substitution mutations at positions functionally equivalent to an amino acid selected from Ala129, Ala141, Ala143, Ser223, Val485, Gly497, Tyr247, Asp599, and Gly633 in the DNA polymerase amino acid sequence, and wherein the recombinant DNA polymerase preferentially incorporates a nucleotide having a blocking group at a faster rate than a nucleotide lacking the blocking group. 3. The recombinant family B archaeal DNA polymerase of claim 2 , wherein the substitution mutation at the position functionally equivalent to Ala129 comprises a mutation to any amino acid other than Met. 4. The recombinant family B archaeal DNA polymerase of claim 2 , wherein the substitution mutation at the position functionally equivalent to Ala 141 comprises a mutation to a non-polar or hydrophobic amino acid. 5. The recombinant family B archaeal DNA polymerase of claim 2 , wherein the substitution mutation at the position functionally equivalent to Ala 143 comprises a mutation to a non-polar or hydrophobic amino acid. 6. The recombinant family B archaeal DNA polymerase of claim 2 , wherein the substitution mutation at the position functionally equivalent to Ser223 comprises a mutation to a polar or uncharged amino acid. 7. The recombinant family B archaeal DNA polymerase of claim 2 , wherein the substitution mutation at the position functionally equivalent to Val485 comprises a mutation to a non-polar or hydrophobic amino acid. 8. The recombinant family B archaeal DNA polymerase of claim 2 , wherein the substitution mutation at the position functionally equivalent to Gly497 comprises a mutation to a non-polar, hydrophobic, or uncharged amino acid. 9. The recombinant family B archaeal DNA polymerase of claim 2 , wherein the substitution mutation at the position functionally equivalent to Tyr247 comprises a mutation to a polar or uncharged amino acid. 10. The recombinant family B archaeal DNA polymerase of claim 2 , wherein the substitution mutation at the position functionally equivalent to Asp599 comprises a mutation to a polar amino acid. 11. The recombinant family B archaeal DNA polymerase of claim 2 , wherein the substitution mutation at the position functionally equivalent to Gly633 comprises a mutation to a non-polar, hydrophobic, or uncharged amino acid. 12. The recombinant family B archaeal DNA polymerase of claim 1 , wherein the DNA polymerase is SEQ ID NO:12, and wherein the DNA polymerase further comprises an amino acid substitution mutation at a position functionally equivalent to Lys349, wherein the substitution mutation is to Ser or Asn. 13. The recombinant family B archaeal DNA polymerase of claim 1 , wherein the DNA polymerase further comprises at least one or at least two amino acid substitution mutations at positions functionally equivalent to an amino acid selected from Lys620 and Val661 in the DNA polymerase amino acid sequence SEQ ID NO:8 or 12, wherein the substitution mutation at Lys620 is to Arg, and wherein the substitution mutation at Val661 is to Asp. 14. The recombinant family B archaeal DNA polymerase of claim 1 , wherein the DNA polymerase further comprises at least one, at least two, at least three, or at least four amino acid substitution mutations at positions functionally equivalent to an amino acid selected from Ala281, Phe283, Trp397, and Gly633 in the DNA polymerase amino acid sequence SEQ ID NO: 12, wherein the substitution mutation at Ala281 is to Phe, wherein the substitution mutation at Phe283 is to Ser, wherein the substitution mutation at Trp397 is to Cys, and wherein the substitution mutation at Gly663 is to Thr. 15. A recombinant family B archaeal DNA polymerase comprising the amino acid sequence chosen from SEQ ID NOs:9, 10, 11, 13, 14, 15, 16, 17, and 12, and comprising two substitution mutations, wherein the first substitution mutation at the position functionally equivalent to Ala408 comprises a mutation to a polar or uncharged amino acid, wherein the second substitution mutation at the position functionally equivalent to Ala409 comprises a mutation to a non-polar or hydrophobic amino acid, and wherein the recombinant DNA polymerase preferentially incorporates a nucleotide having a blocking group at a faster rate than a nucleotide lacking the blocking group. 16. The recombinant family B archaeal DNA polymerase of claim 1 , wherein the family B archaeal DNA polymerase is from a genus selected from Thermococcus, Pyrococcus, Pyrobaculum, Pyrodictium, Aeropyrum and Methanococcus. 17. The recombinant family B archaeal DNA polymerase of claim 1 , wherein the polymerase comprises reduced exonuclease activity as compared to a wild type polymerase. 18. A method for incorporating modified nucleotides into DNA comprising allowing the following components to interact: (i) a recombinant family B archaeal DNA polymerase according to claim 1 , (ii) a DNA template; and (iii) a nucleotide solution. 19. The method of claim 18 , wherein the DNA template comprises a clustered array. 20. A kit for performing a nucleotide incorporation reaction comprising: a recombinant family B archaeal DNA polymerase as defined in claim 1 and a solution comprising modified nucleotides. 21. The kit of claim 20 , wherein the modified nucleotides comprise a detectable label. 22. The kit of claim 20 , wherein the modified nucleotides have been modified at the 3′ sugar hydroxyl such that the substituent is larger in size than the naturally occurring 3′ hydroxyl group. 23. The kit of claim 22 , wherein the modified nucleotides comprise a modified nucleotide or nucleoside molecule comprising a purine or pyrimidine base and a ribose or deoxyribose sugar moiety having a removable 3′-OH blocking group covalently attached thereto, such that the 3′ carbon atom has attached a group of the structure —O—Z wherein Z is any of —C(R′) 2 —O—R″, —C(R′) 2 —N(R″) 2 , —C(R′) 2 —N(H)R″, —C(R′) 2 —S—R″ and —C(R′) 2 —F, wherein each R″ is or is part of a removable protecting group; each R′ is independently a hydrogen atom, an alkyl, substituted alkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclic, acyl, cyano, alkoxy, aryloxy, heteroaryloxy or am

Assignees

Inventors

Classifications

  • involving nucleic acid arrays, e.g. sequencing by hybridisation · CPC title

  • DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase · CPC title

  • C12N9/1252Primary

    DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12077789B2 cover?
Presented herein are altered polymerase enzymes for improved incorporation of nucleotides and nucleotide analogues, in particular altered polymerases that maintain low pre-phasing rates when using ambiently stored polymerases, as well as methods and kits using the same.
Who is the assignee on this patent?
Illumina Inc
What technology area does this patent fall under?
Primary CPC classification C12N9/1252. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).